Slate News Slate Podcasts

The Supreme Court has ruled that presidents enjoy “substantial immunity” from prosecution for crimes committed while in office, which includes absolute immunity for “core constitutional duties” and “presumptive immunity” for “official acts.” 

All good news for one Donald J. Trump. How bad is it for the rest of us? 

Guest: Richard Hasen, law professor at UCLA and director of UCLA Law’s Safeguarding Democracy Project.

Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.

Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme and Rob Gunther.
Learn more about your ad choices. Visit megaphone.fm/adchoices

If you’re questioning the choice of Joe Biden as the Democratic presidential nominee after his debate, uh, performance last week, you’re not alone. But how do you swap candidates this late in the calendar—and who do the Democrats even have as an option?

Guest: David Faris, associate professor of political science at Roosevelt University and author of The Kids Are All Left and It’s Time to Fight Dirty.

Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.

Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme and Rob Gunther.

Public.com+Public Investing: All investing involves risk. Brokerage services for US listed securities, options and bonds in a self-directed brokerage account are offered by Public Investing, member FINRA & SIPC. Not investment advice. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank.Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1828849), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. . See public.com/#disclosures-main for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

In this election year, there’s more criticism and distrust of the media than ever. For veteran journalist Ali Velshi, his belief in the power of journalism is rooted in a family history of pursuing social justice, across continents and generations. On today’s episode of A Word, he joins host Jason Johnson to talk about his career, and his new memoir Small Acts of Courage: A Legacy of Endurance and the Fight for Democracy. 

Guest: Ali Velshi, MSNBC host and author of Small Acts of Courage: A Legacy of Endurance and the Fight for Democracy 

Podcast production by Ahyiana Angel

Want more A Word? Subscribe to Slate Plus to immediately access ad-free listening across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Or, visit slate.com/awordplus to get access wherever you listen.
Learn more about your ad choices. Visit megaphone.fm/adchoices

For years, psychiatrists have been researching new methods to help people with treatment-resistant mental illness. These include severe cases of depression, post-traumatic stress disorder, and other debilitating diagnoses.
One type of drug has seen some positive results in clinical trials: psychedelics like psilocybin, MDMA, ketamine, and LSD.
In professional medical settings, they’re used as a part of a multifaceted approach to mental health treatment, including supervised therapy sessions while a patient is on a drug.
Recently the pharmaceutical manufacturer Lykos petitioned the FDA to approve the psychedelic MDMA as a part of caring for treatment-resistant PTSD.
Earlier this month, an advisory committee to the FDA released their vote of rejecting to approve the drug. 
Now it’s up to the FDA to make the final call, but the odds are not in the favor of Lykos and many psychiatrists and patients who’ve seen positive outcomes as a result of these MDMA-assisted trials.
Psychiatrist and entrepreneur Dave Rabin is one of the doctors pushing to approve psychedelic-assisted therapy. 
On this week’s episode of Well, Now we ask him about the results of his trials using psychedelics in therapy as well as what he thinks the future holds for this field as we wait for the FDA’s final verdict.
If you liked this episode, check out: “As Little Regulation As Guns”: How Social Media Hurts Youth Mental Health
Well, Now is hosted by Dr. Kavita Patel and registered dietitian nutritionist Maya Feller.
Editing and podcast production by Vic Whitley-Berry, with support this week from Kristie Taiwo-Makanjuola.
Editorial oversight from Alicia Montgomery, Vice President of Slate Audio.
Send your comments and recommendations on what to cover to wellnow@slate.com.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The story of IUDs is a story of technology, reproductive rights, shortcomings in communication about women’s health, and politics. 

Guest: Mia Armstrong-Lopez, managing editor at ASU Media Enterprise and author of a recent piece on IUDs for Slate. 

Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.
Learn more about your ad choices. Visit megaphone.fm/adchoices

While most everyone was reacting to Thursday’s Presidential debate, we had our eyes trained on the Supreme Court. It was again (surprise!) bad. SCOTUS determined that sleeping outside was illegal in Grants Pass v Johnson. They limited the scope by which insurrectionists could be charged for their actions on January 6, 2021 in Fischer v United States. The unelected robed leaders then laid a finishing blow in Loper Bright Enterprises v Raimondo, overturning the decades-long guidance of the longstanding Chevron doctrine and upending the ways in which government agencies can regulate the things they regulate like; clean air, water, firearms your retirement account and oh, medical care.  

This term has signaled something especially troubling. While you can certainly be concerned about Trump or Biden being president once again, you should be more worried about how the justices at the Supreme Court have basically made themselves the end-all-be-all of every legislative matter, regardless who wins presidential contests. It should also come as no surprise who will benefit from these decisions (rich people with yachts). 

Host Dahlia Lithwick speaks with Slate’s Mark Joseph Stern and Professor Pam Karlan, co-director of Stanford law school’s Supreme Court Litigation Clinic to go over Friday’s rulings and to break down what it means that federal agencies will no longer be able to, you know, do anything reasonable.

Listen to an interview with a doctor helping unhoused people in Grants Pass, OR.

This is part of Opinionpalooza, Slate’s coverage of the major decisions from the Supreme Court this June. We kicked things off this year by explaining How Originalism Ate the Law. The best way to support our work is by joining Slate Plus. (If you are already a member, consider a donation or merch!)

Want more Amicus? Subscribe to Slate Plus to immediately unlock exclusive SCOTUS analysis and weekly extended episodes. Plus, you’ll access ad-free listening across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Or, visit slate.com/amicusplus to get access wherever you listen.
Learn more about your ad choices. Visit megaphone.fm/adchoices